FDA Rejects Elevar and Hengrui Pharma’s Combination Therapy for Liver Cancer

1. The U.S. Food and Drug Administration (FDA) has rejected the combination therapy for liver cancer developed by Elevar Therapeutics and Hengrui Pharmaceuticals.
2. The combination therapy consists of Elevar's rivoceranib (apatinib) and Hengrui's camrelizumab, which are both targeted therapies for cancer treatment.
3. The FDA's decision was based on the results of a phase 3 clinical trial, which did not meet the primary endpoint of overall survival.
4. The companies had hoped that the combination therapy would provide a new treatment option for patients with advanced liver cancer, who currently have limited options.
5. Despite the setback, Elevar and Hengrui Pharma remain committed to developing new treatments for liver cancer and plan to continue their research and development efforts.